Mechanisms by which Thiazolidinediones Enhance Insulin Action (Q33632888)

28 July 2017

Mechanisms by which Thiazolidinediones Enhance Insulin Action (English)

1 reference

28 July 2017

1 reference

Reginato MJ

1

1 reference

PubMed ID

10322388

28 July 2017

Lazar MA

series ordinal

2

1 reference

28 July 2017

1 December 1999

1 reference

Trends in Endocrinology and Metabolism

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

9-13

1 reference

28 July 2017

1

1 reference

Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes.

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

New concepts for treatment of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

1 reference

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

1 reference

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

A novel antidiabetic drug, troglitazone--reason for hope and concern.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The nuclear receptor superfamily: the second decade

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The RXR heterodimers and orphan receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Nuclear receptor coactivators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Differential activation of peroxisome proliferator-activated receptors by eicosanoids.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The organization, promoter analysis, and expression of the human PPARgamma gene

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Terminal differentiation of human breast cancer through PPAR gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliferator-activated receptor gamma1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Positional cloning of the mouse obese gene and its human homologue

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Mauritius NCD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Peroxisome proliterator-activated receptors, orphans with ligands and functions

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2898%2900110-6

7 January 2021

10.1016/S1043-2760(98)00110-6

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10322388